Biomedical Engineering Reference
In-Depth Information
245. Borst P, Evers R, Kool M, Wijnholds JA. 2000. A family of drug transporters: the multidrug
resistance-associated proteins. J Natl Cancer Inst 16: 1295-1302.
246. Borst P, Oude Elferink R. 2002. Mammalian ABC transporters in health and disease.
Annu Rev Biochem 71: 537-593.
247. Ito KI, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SPC. 2001. Mutation of
Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2
(MRP2), alters substrate specificity and results in loss of methotrexate transport activity.
J Biol Chem 41: 38108-38114.
248. Zeng H, Chen ZS, Belinsky MG, Rea A, Kruh GD. 2001. Transport of methotrexate
(MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyg-
lutamylation on MTX transport. Cancer Res 61: 7225-7232.
249. Chen ZS, Lee K, Walther S, Blanchard-Raftogianis R, Kuwano M, Zeng H, Kruh GD.
2002. Analysis of methotrexate and folate transport by multidrug resistance protein 4
(ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:
3144-3150.
250. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. 2002. Interaction of tyro-
sine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.
Biochim Biophys Acta 1587: 318-325.
251. Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks MK, Houghton JA.
1996. Schedule-dependent efficacy of camptothecins in models of human cancer. Ann N
Y Acad Sci 803: 188-201.
252. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman
LC, Ma MK, Hoffer FA, Meyer WH, et al. 1999. Direct translation of a protracted
irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol
17: 1815-1824.
253. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber
CP, Becton DL, Baruchel S, Pratt C. 2002. Protracted intermittent schedule of topotecan
in children with refractory acute leukemia: a pediatric oncology group study. J Clin Oncol
20: 1617-1624.
254. Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA,
Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, et al. 1999. Phase I and pharma-
cokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients
with solid tumors. J Clin Oncol 17: 685-696.
255. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. 2004. Gefitinib in
patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann
Oncol 15: 1042-1047.
256. Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L,
McCully C, Berg SL, Blaney SM. 2004. Plasma and cerebrospinal fluid pharmacokinetics
of imatinib after administration to nonhuman primates. Clin Cancer Res 10: 2525-2529.
257. Hamada A, Miyano H, Watanabe H, Saito H. 2003. Interaction of imatinib mesylate with
human P-glycoprotein. J Pharmacol Exp Ther 307: 824-828.
258. Scalbert A, Williamson G. 2000. Dietary intake and bioavailability of polyphenols. J Nutr
130(8S Suppl): 2073S-2085S.
259. Arts IC, Hollman PC. 2005. Polyphenols and disease risk in epidemiologic studies. Am
J Clin Nutr 81(1 Suppl): 317S-325S.
Search WWH ::
Custom Search